HCV infection causes dyslipidemia; pretreatment serum total and low-density lipoprotein cholesterol (LDL-C) levels have been associated with treatment response [11]. Low serum lipid levels in HCV infection have been correlated with steatosis, which is associated with more severe liver disease and poorer IFN response [8]. It has been reported that IFNL3-related SNPs may be associated with serum cholesterol levels and hepatic steatosis, which suggests the role for the IFNL3 genotype in the altered lipid metabolism of HCV-infected patients